The Latest
-
Stock via Getty Images
How a scrapped Pfizer drug became a winner for SpringWorks
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
-
Stock via Getty Images
A big moment is coming for psychedelics
Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.
-
Sedat Suna via Getty Images
Novartis scores NFL deal to tackle health outcomes
The non-traditional marketing approach comes amid a potential crackdown on TV drug ads.
-
Anna Moneymaker via Getty Images
Deep DiveHHS layoffs may be illegal, legal experts say
The federal health department sidestepped normal procedures as it laid off 10,000 employees, according to sources. One union has already filed an internal complaint, while at least two law firms are exploring suits.
-
Stock via Getty Images
Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub
Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments.
-
Stephen Maturen via Getty Images
The fallout from UnitedHealth’s CEO slaying
Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.
-
Stock via Getty Images
‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?
The biotech market is taking a beating amid Trump’s turbulent economic policies.
-
Getty Images via Getty Images
Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model
Major changes to the dynamics of the pharmaceutical ecosystem are making executive decisions even tougher.
-
Stock via Getty Images
Pharma’s US manufacturing moment: Where companies are making the biggest moves
The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.
-
Chip Somodevilla via Getty Images
Trump’s tariff tirade and sudden calm keep Big Pharma on its toes
A wild ride in an escalating trade war has torn at Big Pharma’s shares while global markets flag in the back-and-forth winds.
-
Kevin Frayer via Getty Images
US risks losing biotech edge to China, report warns
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.
-
Stock via Getty Images
Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape
The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ROI.
-
Permission granted by Michelle Werner
ProfileHer son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.
-
Stock via Getty Images
A birth control pill for men makes moves in the clinic
So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?
-
Courtesy of Eisai
US vs. EU: When it comes to novel Alzheimer’s drugs, regulators can’t seem to agree
The FDA is much more flexible in approving first-in-class drugs compared to European regulators.
-
Stock via Getty Images
The year’s biggest biotech haul shows investors are still chasing the AI dream
Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.
-
Anna Moneymaker / Staff via Getty Images
Dr. Oz confirmed to lead CMS
Dr. Mehmet Oz, a physician and TV personality, will lead the agency during a turbulent time for federal health programs as the HHS lays off thousands of staffers and Republicans float potential cuts to Medicaid.
-
Kevin Dietsch via Getty Images
OpinionIndustry leaders react to HHS being ‘reduced to a shell’
What healthcare watchdogs have said about the far-reaching job cuts this week.
-
Sarah Silbiger via Getty Images
Is the FDA ‘finished’? Leadership drain hits agency hard.
Amid widespread staff reductions at health agencies, a number of key officials have bid farewell to pharma’s top regulator.
-
Permission granted by Pfizer
ProfileFormer Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’
Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.
-
Stock via Getty Images
With government health info in limbo, drugmakers lose credible sources
The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.
-
Victor Golmer via Getty Images
In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
-
Stock via Getty Images
A recent gene therapy death shines a light on AAV safety
This technology brings both benefits and drawbacks for the field, which is also testing alternatives.
-
Stock via Getty Images
FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.
The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.
-
magicmine, iStock / Getty Images Plus via Getty Images
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.
